A method and device for localized treatment of tissues or organs that were exposed to ischemia and reperfusion (IR) injury, in order to reduce their structural damage and loss of function. The method further includes intra-arterial treatment of transplanted tissues or organs, which are exposed to similar damage of IR and are at risk of impaired function. Leptin antagonist is administered as a bolus injection directly into a re-opened artery, which supplies blood to the tissue or organ involved, immediately after reperfusion. In some cases, after administering a bolus injection of leptin antagonist, the effect of leptin antagonist in the involved organ can be prolonged by deploying a double function drug eluting stent, which elutes leptin antagonist into the lumen, e.g., by sustained release, while eluting antiproliferative drug into the vessel wall to prevent local stenosis, which may appear due to stent deployment.

A biocompatible and biodegradable medical device patch actuating primarily as soft tissue structural reinforcement. The device has a layered architecture, where the primary serves as suturing layer and mechanical support to a thick porous scaffold which can be coated with a mimic-like extra cellular matrix (ECM). The device can be provided to the end user under the format of independent layers that can be cut and assembled to the specific need to the end user and patient. The layers are assembled without the need of any adhesive. Totally haemocompatible and of behavior superior to polytetrafluoroethylene used for any soft tissue repaired, the field of this invention is demonstrated for cardiovascular therapy but should not be limited to it. It is of practical relevance of vein, tendon and hernias and dermal treatments.

A method of delivering a cell derived factors to a subject is described, which includes implanting a matrix material into an intracutaneous location in the subject that results in increased vascularisation and subsequently efficient delivery of the required cell derived factors to the subject. The implanted matrix material can be loaded in-situ or alternatively pre-loaded and inserted into the appropriate location depending on requirements.

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Disclosed herein are delivery systems including coated and uncoated yarns, yarn precursors, threads, fibers, and other substrates for the constant or near-constant release of active compounds, as well as methods for manufacturing such delivery systems. The yarns, yarn precursors, threads, fibers, and other substrates can include a cross-linked hydrophobic elastomer and an active compound. One or more coatings that are impermeable or substantially impermeable to the active compound may partially or fully occlude the yarn or substrate to control release rates of the active compound. The delivery systems may be used in a variety of applications, including the making of articles of clothing, textiles, and fabrics, and may be used in methods of treating various conditions and diseases.

Porous semi-permeable artificial self-attaching scab designed to protect the eroded or injured surfaces. It can be applied on any living being (including plants). The polymerized mesh of the scab is formed when applied on the injured area by a process in which the lysed cells release enzymes that catalyze the reaction. Under this protective surface, the growth of new normal cells that can breathe freely without drying up is promoted. As a result, loss of water, proteins and electrolytes can be avoided; infections can be prevented; and the use of dressing and gauze bandage can be eliminated since they harm the new skin removed. The aqueous thixotropic red-colored fluid applied by brushing or spraying was obtained as a result of the reaction occurred in the container by the combination of the following substances: azosulfamide 1% to 5%+gentian violet 0.004% to 0.007%+dexamethasone 0.001% to 0.003%+pantothenyl alcohol 0.5% to 2%+gentamicin 0.03% to 0.06%.

Devices and methods for treating ischemia and reperfusion injury (IRI) are configured for sustained-release of anti-proliferative drug into the wall of a blood vessel (to prevent in-stent stenosis), and for sustained-release of leptin antagonist into the lumen to be carried by the blood and be uptaken by tissue cells that were subjected to IRI.

The present disclosure provides tissue supports and methods for preparing a cartilage composition for repairing cartilage defects, which is prepared by expanding and integrating small cartilage tissue pieces derived from donor or engineered tissue. The methods and supports described herein promote cell migration and integration of neighboring tissue pieces in culture to form the cartilage composition. Methods of cartilage repair using the cartilage composition are also described.

A controlled release polymer is provided which includes a polymer that has backbone selected from polyesters and polyurethanes, and an amide group with a pendant functional group, where the nitrogen atom of the amide group is part of the polymer backbone, and an active compound dispersed in the polymer. The active compound may be released over time from the controlled release polymer

A method of loading a composition into a structural element of a stent, where the structural element is defined by a lumen and at least one opening to access the lumen. The composition may comprise a therapeutic agent, and wherein at a temperature of 30 C. and at one atmosphere, the composition may be in a solid state or semi-solid state.